rabbit anti egf antibody  (Bioss)

Journal: Brain research bulletin

Article Title: Silibinin protects the ischemic brain in mice by exerting anti-apoptotic effects via the EGFR/ERK pathway.

doi: 10.1016/j.brainresbull.2025.111353

Figure Lengend Snippet: Fig. 3. Silibinin modulated the expression of p-EGFR, p-ERK, cleaved-Caspase3 24 h and 72 h after pMCAO.(A) Immunohistochemical staining of p-EGFR, p-ERK and cleaved-Caspase3 in the Sham, pMCAO, and pMCAO + SIL-M groups 24 h post-ischemia.(BCD) Quantitative analysis of p-EGFR, p-ERK and cleaved-Caspase3. (One- Way ANOVA, *P < 0.05, pMCAO + SIL-M group vs. pMCAO group; n = 6 per group). (E) Immunohistochemical staining of p-EGFR, p-ERK and cleaved-Caspase3 in the Sham, pMCAO, and pMCAO + SIL-M groups 72 h post-ischemia. (FGH) Quantitative analysis of p-EGFR, p-ERK and cleaved-Caspase3. (One-Way ANOVA, **P < 0.01, ***P < 0.001, pMCAO + SIL-M group vs. pMCAO group; n = 6 per group).

Article Snippet: The primary antibodies, diluted in 0.01 M PBS, included: polyclonal rabbit anti-mouse p-EGFR antibody (1:200, Cell Signaling Technology, USA), polyclonal rabbit anti-mouse p-ERK antibody (1:400, Cell Signaling Technology), and monoclonal rabbit anti-mouse cleaved-Caspase-3 antibody (1:300, Cell Signaling Technology).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Brain research bulletin

Article Title: Silibinin protects the ischemic brain in mice by exerting anti-apoptotic effects via the EGFR/ERK pathway.

doi: 10.1016/j.brainresbull.2025.111353

Figure Lengend Snippet: Fig. 4. Silibinin modulated the expression of p-EGFR/EGFR, p-ERK/ERK, cleaved-Caspase3, Bcl2 and Bax 24 h after pMCAO. (A) Representative western blot images of p-EGFR, EGFR, p-ERK, ERK, cleaved-Caspase3, Bcl2 and Bax in the Sham, pMCAO, pMCAO + SIL-M, pMCAO + SIL-M + C225, pMCAO + C225 groups 24 h post- ischemia. (BCDEF) Quantitative analysis of p-EGFR/EGFR, p-ERK/ERK, cleaved-Caspase3, Bcl2 and Bax. (One-Way ANOVA, *P < 0.05, ** P < 0.01, n = 6 per group).

Article Snippet: The primary antibodies, diluted in 0.01 M PBS, included: polyclonal rabbit anti-mouse p-EGFR antibody (1:200, Cell Signaling Technology, USA), polyclonal rabbit anti-mouse p-ERK antibody (1:400, Cell Signaling Technology), and monoclonal rabbit anti-mouse cleaved-Caspase-3 antibody (1:300, Cell Signaling Technology).

Techniques: Expressing, Western Blot

Journal: Brain research bulletin

Article Title: Silibinin protects the ischemic brain in mice by exerting anti-apoptotic effects via the EGFR/ERK pathway.

doi: 10.1016/j.brainresbull.2025.111353

Figure Lengend Snippet: Fig. 5. Silibinin modulated the expression of p-EGFR/EGFR, p-ERK/ERK, cleaved-Caspase3, Bcl2 and Bax 72 h after pMCAO. (A) Representative Western blot images of p-EGFR, EGFR, p-ERK, ERK, cleaved-Caspase3, Bcl2 and Bax in the Sham, pMCAO, pMCAO + SIL-M, pMCAO + SIL-M + C225, pMCAO + C225 groups 72 h post- ischemia. (BCDEF) Quantitative analysis of p-EGFR/EGFR, p-ERK/ERK, cleaved-Caspase3, Bcl2 and Bax. (One-Way ANOVA, *P < 0.05, ** P < 0.01, *** P < 0.001, n = 6 per group).

Article Snippet: The primary antibodies, diluted in 0.01 M PBS, included: polyclonal rabbit anti-mouse p-EGFR antibody (1:200, Cell Signaling Technology, USA), polyclonal rabbit anti-mouse p-ERK antibody (1:400, Cell Signaling Technology), and monoclonal rabbit anti-mouse cleaved-Caspase-3 antibody (1:300, Cell Signaling Technology).

Techniques: Expressing, Western Blot

Journal: Brain research bulletin

Article Title: Silibinin protects the ischemic brain in mice by exerting anti-apoptotic effects via the EGFR/ERK pathway.

doi: 10.1016/j.brainresbull.2025.111353

Figure Lengend Snippet: Fig. 8. C225 attenuated the regulatory effects of silibinin on the expression of p-EGFR, p-ERK, and cleaved-Caspase3 in the brain tissue after infarction. (A) Immunohistochemical staining of p-EGFR, p-ERK and cleaved-Caspase3 in the Sham, pMCAO, pMCAO + SIL-M, pMCAO + SIL-M + C225, pMCAO + C225 groups 72 h post-ischemia. (BCD) Quantitative analysis of p-EGFR, p-ERK and cleaved-Caspase3. (One-Way ANOVA, *P < 0.05, ** P < 0.01, ***P < 0.001; n = 6 per group).

Article Snippet: The primary antibodies, diluted in 0.01 M PBS, included: polyclonal rabbit anti-mouse p-EGFR antibody (1:200, Cell Signaling Technology, USA), polyclonal rabbit anti-mouse p-ERK antibody (1:400, Cell Signaling Technology), and monoclonal rabbit anti-mouse cleaved-Caspase-3 antibody (1:300, Cell Signaling Technology).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Cell Reports Medicine

Article Title: The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR -mutated NSCLC

doi: 10.1016/j.xcrm.2025.101929

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti-Phospho-EGFR (Tyr1068) , Cell Signaling Technology , Cat#2234 RRID: AB_331701.

Techniques: Recombinant, Sequencing, Software